Case Report: dupilumab for severe pruritus in pediatric recessive dystrophic epidermolysis bullosa—a longitudinal clinical assessment and literature review

Linli Liu, Qianying Li, Yan Liu, Kehan Li, Chunshui Yu · 2026

Read Case Report: dupilumab for severe pruritus in pediatric recessive dystrophic epidermolysis bullosa—a longitudinal clinical assessment and literature review by Linli Liu, Qianying Li, Yan Liu, Kehan Li, Chunshui Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13645772.txt.

Description

Linli Liu and four colleagues report the case of a seven-year-old girl with a severe blistering skin disease called recessive dystrophic epidermolysis bullosa, treated for intense itching. Her condition, present from infancy, caused widespread blisters, scarring, mouth and nail damage, and stiffening fingers. Gene tests found two harmful variants, one from each parent, confirming the diagnosis. Standard care had failed to calm the itch-scratch cycle that kept injuring her skin.

Doctors gave her dupilumab, an immune drug used off-label here, alongside routine wound care. Over sixteen weeks her itch score fell from seven to one on a ten-point scale, and pain eased as well. Photos showed fewer open sores, while old scars and finger stiffness stayed. No side effects were blamed on the drug. The authors stress that one uncontrolled case cannot prove the drug caused the gains, yet the change merited reporting.

Catalog record

CREATORLinli Liu, Qianying Li, Yan Liu, Kehan Li, Chunshui Yu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE18 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13645772

Browse the full library · About the Tower of Babel